Vanguard Group Inc. Acquires 1,075,796 Shares of Insmed Incorporated (NASDAQ:INSM)

Vanguard Group Inc. boosted its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,218,973 shares of the biopharmaceutical company’s stock after buying an additional 1,075,796 shares during the quarter. Vanguard Group Inc. owned approximately 0.10% of Insmed worth $1,257,838,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC grew its holdings in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC grew its position in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management bought a new position in shares of Insmed in the fourth quarter worth approximately $47,000. Smartleaf Asset Management LLC increased its holdings in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in Insmed during the fourth quarter valued at about $86,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on INSM shares. Morgan Stanley boosted their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Bank of America lifted their price objective on Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Wells Fargo & Company boosted their price target on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Truist Financial upped their price target on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Finally, Stifel Nicolaus decreased their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.00.

Insmed Price Performance

NASDAQ INSM opened at $77.69 on Friday. The stock has a market capitalization of $14.06 billion, a price-to-earnings ratio of -13.90 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The business’s fifty day moving average price is $78.07 and its 200-day moving average price is $73.93.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. On average, equities analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the transaction, the insider now owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the transaction, the insider now directly owns 102,766 shares of the company’s stock, valued at $6,773,307.06. This trade represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock valued at $42,992,528 in the last ninety days. Corporate insiders own 4.60% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.